KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Amortization of Deferred Charges (2016 - 2018)

Historic Amortization of Deferred Charges for Halozyme Therapeutics (HALO) over the last 7 years, with Q4 2018 value amounting to -$455000.0.

  • Halozyme Therapeutics' Amortization of Deferred Charges rose 2625.61% to -$455000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $1.5 million, marking a year-over-year decrease of 1226.58%. This contributed to the annual value of $1.5 million for FY2018, which is 1226.58% down from last year.
  • Halozyme Therapeutics' Amortization of Deferred Charges amounted to -$455000.0 in Q4 2018, which was up 2625.61% from $303000.0 recorded in Q3 2018.
  • Over the past 5 years, Halozyme Therapeutics' Amortization of Deferred Charges peaked at $3.7 million during Q3 2016, and registered a low of -$6.3 million during Q4 2016.
  • Its 5-year average for Amortization of Deferred Charges is $473500.0, with a median of $423500.0 in 2014.
  • Examining YoY changes over the last 5 years, Halozyme Therapeutics' Amortization of Deferred Charges showed a top increase of 99883.72% in 2016 and a maximum decrease of 184748.6% in 2016.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Amortization of Deferred Charges stood at $415000.0 in 2014, then fell by 13.73% to $358000.0 in 2015, then plummeted by 1847.49% to -$6.3 million in 2016, then surged by 90.14% to -$617000.0 in 2017, then rose by 26.26% to -$455000.0 in 2018.
  • Its Amortization of Deferred Charges stands at -$455000.0 for Q4 2018, versus $303000.0 for Q3 2018 and $345000.0 for Q2 2018.